Story perspectives

Eli Lilly's Diabetes Drug Shows Promise Amid Market Concerns

3/19/2026

Summary

Story summary

Eli Lilly and Co.'s retatrutide showed promising late-stage results for Type 2 diabetes, achieving 15.3% average weight loss overall and 16.8% for trial completers.
HSBC downgraded Eli Lilly and Co.'s stock, citing concerns about the obesity drug market's size and pricing pressures, projecting $80–120 billion by 2032.
Eli Lilly's oral obesity pill, orforglipron, awaits FDA approval in April 2026.
The results contrast strong trial data with regulatory and market uncertainties for obesity drugs.

1 of 1

Story summary

Eli Lilly and Co.'s retatrutide showed promising late-stage results for Type 2 diabetes, achieving 15.3% average weight loss overall and 16.8% for trial completers.
HSBC downgraded Eli Lilly and Co.'s stock, citing concerns about the obesity drug market's size and pricing pressures, projecting $80–120 billion by 2032.
Eli Lilly's oral obesity pill, orforglipron, awaits FDA approval in April 2026.
The results contrast strong trial data with regulatory and market uncertainties for obesity drugs.